Association of Y chromosome haplogroup I with HIV progression, and HAART outcome.

Academic Article

Abstract

  • The host genetic basis of differential outcomes in HIV infection, progression, viral load set point and highly active retroviral therapy (HAART) responses was examined for the common Y haplogroups in European Americans and African Americans. Accelerated progression to acquired immune deficiency syndrome (AIDS) and related death in European Americans among Y chromosome haplogroup I (Y-I) subjects was discovered. Additionally, Y-I haplogroup subjects on HAART took a longer time to HIV-1 viral suppression and were more likely to fail HAART. Both the accelerated progression and longer time to viral suppression results observed in haplogroup Y-I were significant after false-discovery-rate corrections. A higher frequency of AIDS-defining illnesses was also observed in haplogroup Y-I. These effects were independent of the previously identified autosomal AIDS restriction genes. When the Y-I haplogroup subjects were further subdivided into six I subhaplogroups, no one subhaplogroup accounted for the effects on HIV progression, viral load or HAART response. Adjustment of the analyses for population stratification found significant and concordant haplogroup Y-I results. The Y chromosome haplogroup analyses of HIV infection and progression in African Americans were not significant. Our results suggest that one or more loci on the Y chromosome found on haplogroup Y-I have an effect on AIDS progression and treatment responses in European Americans.
  • Published In

  • Human Genetics  Journal
  • Keywords

  • Acquired Immunodeficiency Syndrome, African Americans, Antiretroviral Therapy, Highly Active, Chromosomes, Human, Y, Cohort Studies, European Continental Ancestry Group, HIV Infections, HIV-1, Haplotypes, Humans, Kaplan-Meier Estimate, Male, Polymorphism, Single Nucleotide, Treatment Outcome, United States
  • Digital Object Identifier (doi)

    Authorlist

  • Sezgin E; Lind JM; Shrestha S; Hendrickson S; Goedert JJ; Donfield S; Kirk GD; Phair JP; Troyer JL; O'Brien SJ
  • Start Page

  • 281
  • End Page

  • 294
  • Volume

  • 125
  • Issue

  • 3